| [1] |
DHAR D, BAGLIERI J, KISSELEVA T, et al. Mechanisms of liver fibrosis and its role in liver cancer[J]. Exp Biol Med (Maywood), 2020, 245(2): 96-108. DOI: 10.1177/1535370219898141. |
| [2] |
KHOMICH O, IVANOV AV, BARTOSCH B. Metabolic hallmarks of hepatic stellate cells in liver fibrosis[J]. Cells, 2019, 9(1): 24. DOI: 10.3390/cells9010024. |
| [3] |
NATARAJAN V, HARRIS EN, KIDAMBI S. SECs (sinusoidal endothelial cells), liver microenvironment, and fibrosis[J]. Biomed Res Int, 2017, 2017: 4097205. DOI: 10.1155/2017/4097205. |
| [4] |
GAUL S, LESZCZYNSKA A, ALEGRE F, et al. Hepatocyte pyroptosis and release of inflammasome particles induce stellate cell activation and liver fibrosis[J]. J Hepatol, 2021, 74(1): 156-167. DOI: 10.1016/j.jhep.2020.07.041. |
| [5] |
INZAUGARAT ME, JOHNSON CD, HOLTMANN TM, et al. NLR family pyrin domain-containing 3 inflammasome activation in hepatic stellate cells induces liver fibrosis in mice[J]. Hepatology, 2019, 69(2): 845-859. DOI: 10.1002/hep.30252. |
| [6] |
BAEZA-RAJA B, GOODYEAR A, LIU X, et al. Pharmacological inhibition of P2RX7 ameliorates liver injury by reducing inflammation and fibrosis[J]. PLoS One, 2020, 15(6): e0234038. DOI: 10.1371/journal.pone.0234038. |
| [7] |
SWANSON KV, DENG M, TING JP. The NLRP3 inflammasome: molecular activation and regulation to therapeutics[J]. Nat Rev Immunol, 2019, 19(8): 477-489. DOI: 10.1038/s41577-019-0165-0. |
| [8] |
KELLEY N, JELTEMA D, DUAN Y, et al. The NLRP3 inflammasome: An overview of mechanisms of activation and regulation[J]. Int J Mol Sci, 2019, 20(13): 3328. DOI: 10.3390/ijms20133328. |
| [9] |
ZHANG Y, LI Y, MU T, et al. Hepatic stellate cells specific liposomes with the Toll-like receptor 4 shRNA attenuates liver fibrosis[J]. J Cell Mol Med, 2021, 25(2): 1299-1313. DOI: 10.1111/jcmm.16209. |
| [10] |
DONG Z, ZHUANG Q, NING M, et al. Palmitic acid stimulates NLRP3 inflammasome activation through TLR4-NF-κB signal pathway in hepatic stellate cells[J]. Ann Transl Med, 2020, 8(5): 168. DOI: 10.21037/atm.2020.02.21. |
| [11] |
CAI SM, YANG RQ, LI Y, et al. Angiotensin-(1-7) improves liver fibrosis by regulating the NLRP3 inflammasome via redox balance modulation[J]. Antioxid Redox Signal, 2016, 24(14): 795-812. DOI: 10.1089/ars.2015.6498. |
| [12] |
JIANG S, ZHANG Y, ZHENG JH, et al. Potentiation of hepatic stellate cell activation by extracellular ATP is dependent on P2X7R-mediated NLRP3 inflammasome activation[J]. Pharmacol Res, 2017, 117: 82-93. DOI: 10.1016/j.phrs.2016.11.040. |
| [13] |
JIANG M, CUI BW, WU YL, et al. P2X7R orchestrates the progression of murine hepatic fibrosis by making a feedback loop from macrophage to hepatic stellate cells[J]. Toxicol Lett, 2020, 333: 22-32. DOI: 10.1016/j.toxlet.2020.07.023. |
| [14] |
GASBARRINI A, BORLE AB, CARACENI P, et al. Effect of ethanol on adenosine triphosphate, cytosolic free calcium, and cell injury in rat hepatocytes. Time course and effect of nutritional status[J]. Dig Dis Sci, 1996, 41(11): 2204-2212. DOI: 10.1007/BF02071401. |
| [15] |
SHAN L, JIANG T, CI L, et al. Purine signaling regulating HSCs inflammatory cytokines secretion, activation, and proliferation plays a critical role in alcoholic liver disease[J]. Mol Cell Biochem, 2020, 466(1-2): 91-102. DOI: 10.1007/s11010-020-03691-0. |
| [16] |
LU L, LU Q, CHEN W, et al. Vitamin D(3) protects against diabetic retinopathy by inhibiting high-glucose-induced activation of the ROS/TXNIP/NLRP3 inflammasome pathway[J]. J Diabetes Res, 2018, 2018: 8193523. DOI: 10.1155/2018/8193523. |
| [17] |
SHIMIZU H, TSUBOTA T, KANKI K, et al. All-trans retinoic acid ameliorates hepatic stellate cell activation via suppression of thioredoxin interacting protein expression[J]. J Cell Physiol, 2018, 233(1): 607-616. DOI: 10.1002/jcp.25921. |
| [18] |
LIU X, ZHANG YR, CAI C, et al. Taurine alleviates schistosoma-induced liver injury by inhibiting the TXNIP/NLRP3 inflammasome signal pathway and pyroptosis[J]. Infect Immun, 2019, 87(12): e00732-19. DOI: 10.1128/IAI.00732-19. |
| [19] |
WANG Z, ZHAO Y, SUN R, et al. circ-CBFB upregulates p66Shc to perturb mitochondrial dynamics in APAP-induced liver injury[J]. Cell Death Dis, 2020, 11(11): 953. DOI: 10.1038/s41419-020-03160-y. |
| [20] |
ZHAO Y, WANG Z, FENG D, et al. p66Shc contributes to liver fibrosis through the regulation of mitochondrial reactive oxygen species[J]. Theranostics, 2019, 9(5): 1510-1522. DOI: 10.7150/thno.29620. |
| [21] |
ZHANG B, ZHANG CG, JI LH, et al. Estrogen receptor β selective agonist ameliorates liver cirrhosis in rats by inhibiting the activation and proliferation of hepatic stellate cells[J]. J Gastroenterol Hepatol, 2018, 33(3): 747-755. DOI: 10.1111/jgh.13976. |
| [22] |
LIN L, ZHOU M, QUE R, et al. Saikosaponin-d protects against liver fibrosis by regulating the estrogen receptor-β/NLRP3 inflammasome pathway[J]. Biochem Cell Biol, 2021, 99(5): 666-674. DOI: 10.1139/bcb-2020-0561. |
| [23] |
QUE R, SHEN Y, REN J, et al. Estrogen receptor-β-dependent effects of saikosaponin-d on the suppression of oxidative stress-induced rat hepatic stellate cell activation[J]. Int J Mol Med, 2018, 41(3): 1357-1364. DOI: 10.3892/ijmm.2017.3349. |
| [24] |
XIONG M, LI J, YANG S, et al. Influence of gender and reproductive factors on liver fibrosis in patients with chronic hepatitis B infection[J]. Clin Transl Gastroenterol, 2019, 10(10): e00085. DOI: 10.14309/ctg.0000000000000085. |
| [25] |
LIMA-JUNIOR DS, MINEO T, CALICH V, et al. Dectin-1 activation during leishmania amazonensis phagocytosis prompts Syk-dependent reactive oxygen species production to trigger inflammasome assembly and restriction of parasite replication[J]. J Immunol, 2017, 199(6): 2055-2068. DOI: 10.4049/jimmunol.1700258. |
| [26] |
LU YQ, ZHONG S, MENG N, et al. NLRP3 inflammasome activation results in liver inflammation and fibrosis in mice infected with Schistosoma japonicum in a Syk-dependent manner[J]. Sci Rep, 2017, 7(1): 8120. DOI: 10.1038/s41598-017-08689-1 |
| [27] |
LIN YC, HUANG DY, WANG JS, et al. Syk is involved in NLRP3 inflammasome-mediated caspase-1 activation through adaptor ASC phosphorylation and enhanced oligomerization[J]. J Leukoc Biol, 2015, 97(5): 825-835. DOI: 10.1189/jlb.3HI0814-371RR. |
| [28] |
YOON YC, FANG Z, LEE JE, et al. Selonsertib inhibits liver fibrosis via downregulation of ASK1/MAPK pathway of hepatic stellate cells[J]. Biomol Ther (Seoul), 2020, 28(6): 527-536. DOI: 10.4062/biomolther.2020.016. |
| [29] |
SANDALL CF, MACDONALD JA. Effects of phosphorylation on the NLRP3 inflammasome[J]. Arch Biochem Biophys, 2019, 670: 43-57. DOI: 10.1016/j.abb.2019.02.020. |
| [30] |
SCHUSTER-GAUL S, GEISLER LJ, MCGEOUGH MD, et al. ASK1 inhibition reduces cell death and hepatic fibrosis in an Nlrp3 mutant liver injury model[J]. JCI Insight, 2020, 5(2). DOI: 10.1172/jci.insight.123294. |
| [31] |
LOOMBA R, LAWITZ E, MANTRY PS, et al. The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial[J]. Hepatology, 2018, 67(2): 549-559. DOI: 10.1002/hep.29514. |
| [32] |
MCQUITTY CE, WILLIAMS R, CHOKSHI S, et al. Immunomodulatory role of the extracellular matrix within the liver disease microenvironment[J]. Front Immunol, 2020, 11: 574276. DOI: 10.3389/fimmu.2020.574276. |
| [33] |
QIN CC, LIU YN, HU Y, et al. Macrophage inflammatory protein-2 as mediator of inflammation in acute liver injury[J]. World J Gastroenterol, 2017, 23(17): 3043-3052. DOI: 10.3748/wjg.v23.i17.3043. |
| [34] |
HOLTMANN TM, INZAUGARAT ME, KNORR J, et al. Bile acids activate NLRP3 inflammasome, promoting murine liver inflammation or fibrosis in a cell type-specific manner[J]. Cells, 2021, 10(10): 2618. DOI: 10.3390/cells10102618. |
| [35] |
YAN W, SHEN Y, HUANG J, et al. MCC950 ameliorates acute liver injury through modulating macrophage polarization and myeloid-derived suppressor cells function[J]. Front Med (Lausanne), 2021, 8: 752223. DOI: 10.3389/fmed.2021.752223. |
| [36] |
BERINGER A, MIOSSEC P. IL-17 and TNF-α co-operation contributes to the proinflammatory response of hepatic stellate cells[J]. Clin Exp Immunol, 2019, 198(1): 111-120. DOI: 10.1111/cei.13316. |
| [37] |
KAGAN P, SULTAN M, TACHLYTSKI I, et al. Both MAPK and STAT3 signal transduction pathways are necessary for IL-6-dependent hepatic stellate cells activation[J]. PLoS One, 2017, 12(5): e0176173. DOI: 10.1371/journal.pone.0176173. |
| [38] |
GE S, YANG W, CHEN H, et al. MyD88 in macrophages enhances liver fibrosis by activation of NLRP3 inflammasome in HSCs[J]. Int J Mol Sci, 2021, 22(22): 12413. DOI: 10.3390/ijms222212413. |
| [39] |
WREE A, MCGEOUGH MD, INZAUGARAT ME, et al. NLRP3 inflammasome driven liver injury and fibrosis: Roles of IL-17 and TNF in mice[J]. Hepatology, 2018, 67(2): 736-749. DOI: 10.1002/hep.29523. |
| [40] |
ZHOU Z, XU MJ, CAI Y, et al. Neutrophil-hepatic stellate cell interactions promote fibrosis in experimental steatohepatitis[J]. Cell Mol Gastroenterol Hepatol, 2018, 5(3): 399-413. DOI: 10.1016/j.jcmgh.2018.01.003. |
| [41] |
KANG H, SEO E, OH YS, et al. TGF-β activates NLRP3 inflammasome by an autocrine production of TGF-β in LX-2 human hepatic stellate cells[J]. Mol Cell Biochem, 2022, 477(5): 1329-1338. DOI: 10.1007/s11010-022-04369-5. |
| [42] |
WANG H, LIU S, WANG Y, et al. Nod-like receptor protein 3 inflammasome activation by Escherichia coli RNA induces transforming growth factor beta 1 secretion in hepatic stellate cells[J]. Bosn J Basic Med Sci, 2016, 16(2): 126-131. DOI: 10.17305/bjbms.2016.699. |
| [43] |
LEE KY, ITO K, HAYASHI R, et al. NF-kappaB and activator protein 1 response elements and the role of histone modifications in IL-1beta-induced TGF-beta1 gene transcription[J]. J Immunol, 2006, 176(1): 603-615. DOI: 10.4049/jimmunol.176.1.603. |
| [44] |
REITER FP, WIMMER R, WOTTKE L, et al. Role of interleukin-1 and its antagonism of hepatic stellate cell proliferation and liver fibrosis in the Abcb4(-/-) mouse model[J]. World J Hepatol, 2016, 8(8): 401-410. DOI: 10.4254/wjh.v8.i8.401. |
| [45] |
YAPING Z, YING W, LUQIN D, et al. Mechanism of interleukin-1β-induced proliferation in rat hepatic stellate cells from different levels of signal transduction[J]. APMIS, 2014, 122(5): 392-398. DOI: 10.1111/apm.12155. |
| [46] |
FRISSEN M, LIAO L, SCHNEIDER KM, et al. Bidirectional role of NLRP3 during acute and chronic cholestaticliver injury[J]. Hepatology, 2021, 73(5): 1836-1854. DOI: 10.1002/hep.31494. |
| [47] |
SCHWAID AG, SPENCER KB. Strategies for targeting the NLRP3 inflammasome in the clinical and preclinical space[J]. J Med Chem, 2021, 64(1): 101-122. DOI: 10.1021/acs.jmedchem.0c01307. |
| [48] |
KENNEDY CR, GOYA GROCIN A, KOVAČIČ T, et al. A probe for NLRP3 inflammasome inhibitor MCC950 identifies carbonic anhydrase 2 as a novel target[J]. ACS Chem Biol, 2021, 16(6): 982-990. DOI: 10.1021/acschembio.1c00218. |
| [49] |
MASSARO MG, POMPILI M, SICIGNANO LL, et al. Improvement of liver involvement in familial mediterranean fever after the introduction of canakinumab: A case report[J]. Mediterr J Hematol Infect Dis, 2020, 12(1): e2020059. DOI: 10.4084/MJHID.2020.059. |
DownLoad:
